Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Isarna Therapeutics Raises Euro 13 Million from New and Current Investors

Published: Wednesday, January 08, 2014
Last Updated: Wednesday, January 08, 2014
Bookmark and Share
Euro 13 million raised in equity from AT NewTec and MIG-managed funds.

Isarna Therapeutics GmbH has announced that it has raised Euro 13 million (USD 17.8 Mio) in equity from new private investor AT NewTec and current investors, MIG-managed funds.

Proceeds will be used to advance the company's pipeline of next generation oligonucleotides that inhibit various isoforms of TGF-β, a key molecular pathway implicated in mechanisms used by cancer cells to evade immune system detection and to aid in tumor proliferation.

"This financing supports our position as the leaders in utilizing TGF-β as a unique target for cancer immunotherapy and enables us to continue the rapid development of our pipeline toward the clinic," said Dr. Philippe Calais, Chief Executive Officer at Isarna Therapeutics. "We are fortunate to have the continued commitment from MIG, our largest shareholder, and welcome the new investment from AT NewTec.”

“MIG is convinced that an immunotherapy approach to treating cancer has the potential to change the paradigm of current standard of care,” added Dr. Matthias Kromayer, Managing Director of MIG Verwaltungs AG. “We have great confidence in both Isarna’s pioneering approach to leveraging TGF-β and the company’s management.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Isarna Announces Orphan Drug Designation for ISTH0036
Orphan drug designation in the European Union to treat advanced-stage glaucoma.
Saturday, May 23, 2015
Isarna Presents Positive Preclinical Results Supporting Development of ISTH0036
Oral and poster presentations given at ARVO 2015 annual conference.
Thursday, May 14, 2015
Isarna Initiates First-in-Human Phase I Trial for ISTH0036
Phase I trial designed to evaluate the safety and long-term tolerability of ISTH0036 in patients with advanced glaucoma.
Friday, April 17, 2015
Isarna Therapeutics Unveils New Selective TGF-beta Antagonist Program
First-in-human study in advanced-stage glaucoma to begin in 1H2015.
Friday, January 09, 2015
Isarna Therapeutics Raises €5.5 Million
Elizabeth Czerepak joins Company’s management team as Chief Financial Officer and Chief Business Officer.
Friday, April 25, 2014
Isarna Therapeutics Enters into a Strategic Manufacturing Agreement with Sanofi
Sanofi will manufacture clinical- and commercial-grade antisense oligonucleotide (ASO) compounds for Isarna.
Friday, January 10, 2014
Scientific News
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Some Women With PCOS May Have Adrenal Disorder
Researchers at NIH have found that a subgroup of women with PCOS, a leading cause of infertility, may produce excess adrenal hormones.
Alzheimer's Genetics Point To New Research Direction
A University of Adelaide analysis of genetic mutations which cause early-onset Alzheimer’s disease suggests a new focus for research into the causes of the disease.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Manufactured Stem Cells To Advance Clinical Research
Clinical-grade cell line will enable development of new therapies and accelerate early-stage clinical research.
Faster Detection of Pathogens in the Lungs
Thanks to new molecular-based methods, mycobacterial pathogens that cause pulmonary infections or tuberculosis can now be detected much more quickly.
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Anthrax Vaccine Protects Monkeys
Vaccination with the anthrax capsule—a naturally occurring component of the bacterium that causes the disease—completely protected monkeys from lethal anthrax infection, according to a recently published study.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!